Jlb & Associates Inc Gilead Sciences, Inc. Transaction History

Jlb & Associates Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 29, 2019	SELL	$62.51 - $69.0 $588,281 - $649,359	-9,411 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$61.87 - $69.38 $46,711 - $52,381	755 Added 8.72%	9,411 $841,000
Q1 2019 Apr 30, 2019	BUY	$62.53 - $70.05 $53,963 - $60,453	863 Added 11.07%	8,656 $709,000
Q4 2018 Jan 11, 2019	BUY	$60.54 - $79.0 $304,697 - $397,607	5,033 Added 182.36%	7,793 $580,000
Q3 2018 Oct 10, 2018	SELL	$71.28 - $78.92 $842,672 - $932,992	-11,822 Reduced 81.07%	2,760 $239,000

Q2 2018 Jul 09, 2018	SELL	$64.88 - $75.68 $6.92 Million - $8.07 Million	-106,611 Reduced 87.97%	14,582 $1.06 Million
Q1 2018 Apr 23, 2018	BUY	$72.84 - $88.8 $110,498 - $134,709	1,517 Added 1.27%	121,193 $9.14 Million
Q4 2017 Jan 24, 2018	BUY	$71.15 - $83.52 $545,222 - $640,013	7,663 Added 6.84%	119,676 $8.57 Million
Q3 2017 Oct 12, 2017	BUY	$72.11 - $85.47 $8.08 Million - $9.57 Million	112,013	112,013 $9.08 Million

1,885

8.71M

8.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $85.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Jlb & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Jlb & Associates Inc with notifications on news.